Jiangsu Recbio Technology Co., Ltd. Class H (2179) AI Stock Analysis

• Market Cap: HK$2.63B
• Dividend Yield: N/A
• Average Volume (3M): 18.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.30
• Revenue Growth: N/A
• EPS Growth: -18.99%
• Country: HK
• Employees: 531
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.78
• Shares Outstanding: 316,138,700
• 10 Day Avg. Volume: 1,300
• 30 Day Avg. Volume: 18,233
• PEG Ratio: 3.04
• Price to Book (P/B): 8.14
• Price to Sales (P/S): 159.51
• P/FCF Ratio: -6.77
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: HK$5.50 ▲(0.18% Upside)

The overall stock score is heavily influenced by the company's poor financial performance and valuation metrics. The financial health is precarious with declining revenue, persistent losses, and negative cash flows. Technical analysis indicates bearish momentum, with the stock trading below key moving averages. The negative P/E ratio further underscores the lack of profitability. These factors collectively result in a low overall stock score.

Positive Factors

Business Scope Expansion

Expanding business scope to include bio-based materials can enhance market positioning and operational capabilities, supporting long-term growth.

International Market Expansion

The partnership for HPV vaccine expansion into India and UNICEF markets strengthens international presence and leverages global demand, aiding sustainable growth.

Share Liquidity Enhancement

Increasing H share liquidity can improve market position and investor confidence, supporting long-term financial stability and market access.

Negative Factors

Declining Revenue

Declining revenue reflects challenges in market demand or competitive positioning, potentially impacting long-term financial health and growth prospects.

Negative Cash Flow

Persistent negative cash flow indicates financial strain and limits the ability to invest in growth opportunities, posing risks to long-term viability.

High Leverage

High leverage increases financial risk and limits flexibility, potentially affecting the company's ability to navigate economic downturns or invest in growth.

Jiangsu Recbio Technology Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Jiangsu Recbio Technology Co., Ltd. is a biotechnology company based in Jiangsu, China, focusing on the research, development, and commercialization of innovative biopharmaceutical products. The company primarily operates in the healthcare sector, specializing in vaccine development and other biologics aimed at combating infectious diseases. Recbio is dedicated to leveraging advanced technologies to create effective and safe vaccines, contributing to public health and disease prevention globally.

How the Company Makes Money

Jiangsu Recbio Technology Co., Ltd. generates revenue through several key streams, primarily from the sale of vaccines and related biopharmaceutical products. The company engages in research and development (R&D) of vaccines, which, once commercialized, are sold to governments, healthcare providers, and pharmaceutical distributors. Additionally, Recbio may enter into partnerships and collaborations with larger pharmaceutical companies for co-development and distribution of its products, providing a significant source of income through licensing fees and milestone payments. Grants and funding from public health organizations and governmental bodies for vaccine development projects also contribute to the company's revenue. Furthermore, strategic partnerships with academic institutions and participation in clinical trials can enhance its product pipeline and market presence, ultimately driving sales and profitability.

Jiangsu Recbio Technology Co., Ltd. Class H Financial Statement Overview

Summary

Jiangsu Recbio Technology Co., Ltd. faces significant financial challenges, including declining revenue, persistent losses, and negative cash flows. High leverage and negative equity in some periods pose additional risks. Despite slight improvements in certain balance sheet metrics, the financial health remains precarious.

Income Statement

The income statement reveals a challenging financial position. Revenue has decreased from 2023 to 2024, indicating a negative growth trend. Gross Profit Margin is positive, but Net Profit Margin is significantly negative due to substantial net losses, reflecting high operational costs and inefficiencies. The company is experiencing negative EBIT and EBITDA Margins, highlighting ongoing operational challenges and lack of profitability.

Balance Sheet

The balance sheet indicates moderate risk. The company has a negative equity position in some past years, which has improved slightly but remains vulnerable. High Debt-to-Equity ratios suggest significant leverage, posing financial risk. The Return on Equity (ROE) is negative, reflecting continued losses. However, the company maintains a reasonable level of assets relative to liabilities, providing some stability.

Cash Flow

Cash flow analysis shows a concerning trend. Operating cash flow is consistently negative, reflecting cash outflows from operations. Free Cash Flow is also negative, indicating that the company is not generating sufficient cash to cover capital expenditures. The lack of positive cash flow growth suggests ongoing financial strain and limited liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	29.11M	27.00M	30.38M	5.33M	6.20M	1.46M
Gross Profit	26.20M	15.95M	22.34M	5.33M	6.20M	1.46M
EBITDA	-577.66M	-523.97M	-569.87M	-847.67M	-590.00M	-134.91M
Net Income	-653.91M	-562.39M	-571.96M	-719.20M	-657.56M	-179.40M
Balance Sheet
Total Assets	1.54B	1.94B	2.19B	2.31B	1.92B	1.05B
Cash, Cash Equivalents and Short-Term Investments	104.20M	448.31M	837.76M	1.33B	1.18B	681.71M
Total Debt	839.95M	889.10M	650.79M	282.63M	76.72M	26.13M
Total Liabilities	1.37B	1.41B	1.12B	656.53M	245.92M	2.06B
Stockholders Equity	177.63M	529.32M	1.07B	1.66B	1.67B	-1.01B
Cash Flow
Free Cash Flow	-278.63M	-636.66M	-862.18M	-888.04M	-710.79M	-241.07M
Operating Cash Flow	-184.88M	-464.82M	-638.07M	-579.54M	-472.92M	-70.34M
Investing Cash Flow	-214.61M	-279.04M	9.42M	-378.43M	68.70M	-258.59M
Financing Cash Flow	0.00	218.06M	275.27M	839.44M	1.23B	680.38M

Jiangsu Recbio Technology Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.49
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2179, the sentiment is Negative. The current price of 5.49 is below the 20-day moving average (MA) of 5.68, below the 50-day MA of 6.32, and below the 200-day MA of 7.53, indicating a bearish trend. The MACD of -0.26 indicates Negative momentum. The RSI at 17.59 is Positive, neither overbought nor oversold. The STOCH value of 46.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2179.

Jiangsu Recbio Technology Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	58 Neutral	HK$1.50B	184.76	0.99%	―	9.41%	-32.69%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
3681	45 Neutral	HK$2.05B	-10.37	-55.33%	―	-100.00%	30.68%
2616	42 Neutral	HK$8.12B	-17.93	-95.84%	―	-55.64%	-158.67%
2157	40 Underperform	HK$9.81B	-46.89	-21.42%	―	240.05%	-140.09%
2179	39 Underperform	HK$2.63B	-3.72	-129.05%	―	―	-18.99%

Jiangsu Recbio Technology Co., Ltd. Class H Corporate Events

Jiangsu Recbio Technology Announces Key Governance Changes

Jiangsu Recbio Technology Co., Ltd. has announced an extraordinary general meeting scheduled for December 19, 2025, to discuss significant corporate governance changes, including the abolishment of the Supervisory Board and amendments to the Articles of Association. The meeting will also address the election of new directors and amendments to management rules, potentially impacting the company’s governance structure and operational strategies.

Jiangsu Recbio Announces Board Composition and Roles

Jiangsu Recbio Technology Co., Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement provides insights into the company’s governance structure, which is crucial for its strategic direction and operational management, potentially impacting stakeholder confidence and the company’s positioning in the biotechnology sector.

Jiangsu Recbio Strengthens Governance with New Nomination Committee

Jiangsu Recbio Technology Co., Ltd. has established a Nomination Committee to enhance its governance structure by regulating the appointment of directors and senior management. This move aims to rationalize the board’s composition and improve the company’s operational efficiency, potentially impacting its industry positioning positively.

Jiangsu Recbio Enhances Governance with New Committee

Jiangsu Recbio Technology Co., Ltd. has established a Remuneration and Appraisal Committee to enhance its governance structure by formulating appraisal standards and remuneration plans for directors and senior management. This move aims to create a scientific and standardized incentive mechanism, potentially strengthening the company’s operational efficiency and stakeholder confidence.

Jiangsu Recbio Technology Strengthens Governance with New Audit Committee

Jiangsu Recbio Technology Co., Ltd. has established an audit committee as part of its board to enhance decision-making, improve internal controls, and ensure effective supervision and management. The committee, composed mainly of independent non-executive directors with financial expertise, will oversee financial reviews, internal audits, and risk assessments, thereby strengthening the company’s governance structure.

Jiangsu Recbio Announces Leadership Changes and New Appointments

Jiangsu Recbio Technology Co., Ltd. has announced significant changes in its leadership structure, including the resignation of three directors and the appointment of new directors. The company is actively seeking to maintain gender diversity on its board and is committed to compliance with corporate governance standards. The new appointments are expected to bring fresh perspectives and leadership to the company, potentially impacting its strategic direction and market positioning.

Jiangsu Recbio Completes Capital Alteration and Updates Business License

Jiangsu Recbio Technology Co., Ltd. has completed the industrial and commercial registration for its registered capital alteration, following the issuance of domestic shares to target subscribers. The company’s registered capital has increased from RMB482,963,000 to RMB626,075,702, and it has obtained a renewed business license. This change reflects a significant shift in the company’s shareholding structure, with domestic shares now accounting for a larger portion of the total share capital. These amendments to the Articles of Association were authorized by the Board of Directors and do not require further approval from the general meeting, indicating streamlined governance processes.

Jiangsu Recbio Expands Drug Production License for Shingles Vaccine

Jiangsu Recbio Technology Co., Ltd. has received approval to expand its Drug Production License to include the recombinant shingles vaccine and its adjuvant components. This expansion enhances the company’s R&D and production capabilities, aligning with the growing market demand for shingles vaccines due to population aging. The approval signifies regulatory recognition of the company’s quality management and production standards, positioning it for future commercialization and strengthening its competitiveness in the biopharmaceutical industry.

Jiangsu Recbio Completes Capital Verification for Domestic Shares Issuance

Jiangsu Recbio Technology Co., Ltd. has completed the payment and capital verification for its issuance of 143,112,702 domestic shares, priced at RMB5.59 each, resulting in net proceeds of RMB789,985,366.85. This successful issuance marks a significant step in the company’s financial operations, potentially enhancing its market positioning and providing additional resources for future growth initiatives.